Nektar Therapeutics (NKTR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting opened by Vice President, Legal and Corporate Counsel, with board members, executive team, and auditors present.
Formal business included voting on four proposals, followed by business highlights and a Q&A session.
Shareholder proposals
Four proposals: election of one director, amendment to increase shares in the 2017 Performance Incentive Plan, ratification of auditors, and a non-binding advisory vote on executive compensation.
Overview of voting outcomes
All four proposals were approved by a majority of shares voted, including director election, plan amendment, auditor ratification, and executive compensation.
Final results to be published in a Form 8-K within four business days.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Nektar Therapeutics
- Global phase III trials for a novel Treg agonist target broad immune diseases, with first data in 2028.NKTR
Jefferies Global Healthcare Conference 20263 Jun 2026 - REZPEG advances to Phase 3 after strong Phase 2 data and $476M raised for late-stage trials.NKTR
Q4 202515 May 2026 - Strong cash, narrowed losses, and positive clinical data drive late-stage program progress.NKTR
Q1 202611 May 2026 - Annual meeting seeks approval for director, incentive plan shares, auditor, and say-on-pay.NKTR
Proxy filing24 Apr 2026 - Proxy covers director election, equity plan amendment, auditor ratification, and say-on-pay.NKTR
Proxy filing24 Apr 2026 - Rezpegaldesleukin showed durable efficacy and strong safety at 52 weeks, supporting first-line use.NKTR
Study update20 Apr 2026 - REZPEG demonstrates durable efficacy and safety, setting new standards in immune-mediated diseases.NKTR
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Durable efficacy and deepening responses maintained with strong safety over 52 weeks.NKTR
Study result10 Feb 2026 - REZPEG shows strong efficacy in atopic dermatitis, with pivotal data expected in early 2025.NKTR
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026